8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
Public ClinicalTrials.gov record NCT01570686. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the effect of food on aliskiren's efficacy, pharmacokinetics and safety following an oral dose of 300 mg, given once daily under light meal versus fasted conditions.
Study identification
- NCT ID
- NCT01570686
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 589 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2012 (Type not available)
- Primary completion
- Nov 2012 (Actual)
- Completion
- Nov 2012 (Actual)
- Last update posted
- Jan 22, 2014
2012
United States locations
- U.S. sites
- 43
- U.S. states
- 18
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Los Angeles | California | 90057 | — |
| Novartis Investigative Site | Riverside | California | 92506 | — |
| Novartis Investigative Site | Santa Monica | California | 90404 | — |
| Novartis Investigative Site | Walnut Creek | California | 94598 | — |
| Novartis Investigative Site | Westlake Village | California | 91361 | — |
| Novartis Investigative Site | Coral Gables | Florida | 33134 | — |
| Novartis Investigative Site | Miami | Florida | 33169 | — |
| Novartis Investigative Site | South Miami | Florida | 33143 | — |
| Novartis Investigative Site | Chicago | Illinois | 60607 | — |
| Novartis Investigative Site | Chicago | Illinois | 60610 | — |
| Novartis Investigative Site | Evansville | Indiana | 47712 | — |
| Novartis Investigative Site | Topeka | Kansas | 66606 | — |
| Novartis Investigative Site | Opelousas | Louisiana | 70570 | — |
| Novartis Investigative Site | Chaska | Minnesota | 55318 | — |
| Novartis Investigative Site | Edina | Minnesota | 55435 | — |
| Novartis Investigative Site | Saint Paul | Minnesota | 55114 | — |
| Novartis Investigative Site | Jackson | Mississippi | 39209 | — |
| Novartis Investigative Site | Picayune | Mississippi | 39466 | — |
| Novartis Investigative Site | St Louis | Missouri | 63141 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28209 | — |
| Novartis Investigative Site | Greensboro | North Carolina | 27401 | — |
| Novartis Investigative Site | Greensboro | North Carolina | 27408 | — |
| Novartis Investigative Site | Salisbury | North Carolina | 28144 | — |
| Novartis Investigative Site | Shelby | North Carolina | 28152 | — |
| Novartis Investigative Site | Winston-Salem | North Carolina | 27103 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45246 | — |
| Novartis Investigative Site | Columbus | Ohio | 43213 | — |
| Novartis Investigative Site | Lyndhurst | Ohio | 44124 | — |
| Novartis Investigative Site | Marion | Ohio | 43302 | — |
| Novartis Investigative Site | Norman | Oklahoma | 73069 | — |
| Novartis Investigative Site | Eugene | Oregon | 97404 | — |
| Novartis Investigative Site | Oregon City | Oregon | 97045 | — |
| Novartis Investigative Site | Portland | Oregon | 97239 | — |
| Novartis Investigative Site | Knoxville | Tennessee | 37920 | — |
| Novartis Investigative Site | Beaumont | Texas | 77702 | — |
| Novartis Investigative Site | Houston | Texas | 77081 | — |
| Novartis Investigative Site | Lake Jackson | Texas | 77566 | — |
| Novartis Investigative Site | Pasadena | Texas | 77504 | — |
| Novartis Investigative Site | Centerville | Utah | 84104 | — |
| Novartis Investigative Site | Arlington | Virginia | 22203 | — |
| Novartis Investigative Site | Ettrick | Virginia | 23803 | — |
| Novartis Investigative Site | Midlothian | Virginia | 23114 | — |
| Novartis Investigative Site | Port Orchard | Washington | 98366 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01570686, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2014 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01570686 live on ClinicalTrials.gov.